AVEO Pharmaceuticals, Inc. (AVEO) Receives $5.50 Consensus Target Price from Brokerages
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has earned an average rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $5.50.
A number of brokerages have issued reports on AVEO. BidaskClub raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. HC Wainwright began coverage on AVEO Pharmaceuticals in a report on Thursday, August 16th. They set a “buy” rating and a $6.50 price objective for the company.
In related news, major shareholder Equity Opportunities Iv Growth acquired 663,716 shares of the business’s stock in a transaction on Tuesday, August 21st. The stock was bought at an average cost of $2.26 per share, with a total value of $1,499,998.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have acquired 919,611 shares of company stock valued at $2,002,558. Company insiders own 4.40% of the company’s stock.
Shares of AVEO stock opened at $2.86 on Friday. The firm has a market capitalization of $340.43 million, a P/E ratio of -17.88 and a beta of 1.62. AVEO Pharmaceuticals has a one year low of $1.86 and a one year high of $4.15. The company has a debt-to-equity ratio of -0.36, a current ratio of 1.16 and a quick ratio of 1.16.
AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.09). The company had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $1.35 million. sell-side analysts predict that AVEO Pharmaceuticals will post -0.26 earnings per share for the current fiscal year.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Featured Story: Determine Your Level of Risk Tolerance
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.